Is Ibrance a subsidiary of Pfizer?

No. Ibrance is a product brand of Pfizer Inc., not a subsidiary. The drug was developed internally and is wholly owned by the company.

Is Ibrance publicly traded?

No. Ibrance is a drug. Its owner Pfizer trades on the NYSE under ticker PFE.

When was Ibrance approved?

The FDA granted accelerated approval in February 2015 and regular approval in 2016. A male breast cancer indication was added in 2019.

Ibrance was discovered by Pfizer's internal oncology research program. The compound palbociclib originated in Pfizer laboratories with late-stage clinical development driven through academic collaboration including UCLA.

What is Ibrance's market position?

Ibrance is the first CDK4/6 inhibitor and historically the class leader, with peak annual sales of approximately $5.4 billion. It competes with Kisqali and Verzenio and faces approaching generic competition.

Healthcare & Pharmaceuticals

Who Owns Ibrance?

Ibrance is owned by Pfizer Inc. (NYSE: PFE), a publicly traded American pharmaceutical company headquartered in New York City. Ibrance (palbociclib) is an internally developed Pfizer oncology product first approved by the FDA in February 2015 for HR-positive, HER2-negative advanced breast cancer. It remains one of Pfizer's largest oncology revenue products.

Parent Company

Pfizer Inc.

Founded

2015

Status

Publicly Traded

Headquarters

New York, New York, USA

Ibrance Timeline

1849

Pfizer Inc.

Parent company established in New York, New York, USA

Company Founded

2015

Ibrance

Founded by Pfizer Inc. (internal development)

Founded

GlobalOfficial Website

Who Owns Ibrance?

Parent Company: Pfizer Inc.
Ownership Type: Product line
Company Type: Publicly Traded
Stock Ticker: NYSE: PFE

Brand	Parent Company	Ownership Type
Ibrance	Pfizer Inc.	Product line

Where to Buy

Disclosure: We may earn commission from purchases

Ibrance on Amazon

History of Ibrance

Founded: 2015
Founders: Pfizer Inc. (internal development)

Palbociclib emerged from Pfizer's internal cancer research program targeting cyclin-dependent kinases, the enzymes that drive cell division. The compound, initially designated PD-0332991, spent years in Pfizer's pipeline before breakthrough clinical data at UCLA's Jonsson Comprehensive Cancer Center showed dramatic progression-free survival benefit in estrogen receptor-positive breast cancer, prompting accelerated development.

The FDA granted accelerated approval on February 3, 2015, for postmenopausal women with HR-positive, HER2-negative advanced breast cancer, based on the PALOMA-1 trial showing roughly doubled progression-free survival versus letrozole alone. The approval was a landmark: Ibrance was the first CDK4/6 inhibitor to market, creating an entirely new drug class in breast cancer.

Regular approval followed in 2016 after the confirmatory PALOMA-2 trial, and the indication expanded to men in 2019. Competitors entered within two years: Novartis launched Kisqali (ribociclib) in 2017 and Eli Lilly launched Verzenio (abemaciclib) in 2017, each with label expansions into early-stage disease that Ibrance failed to secure after its adjuvant trials disappointed.

Ibrance peaked at approximately $5.4 billion in annual revenue and became one of Pfizer's largest products during its first decade. As the 2020s progressed, Ibrance's share of the class declined as Verzenio's superior overall survival data in adjuvant settings shifted prescribing, and patent expiry approached in the late 2020s, opening the path to generic competition.

About Pfizer Inc.

What does Pfizer own?
Pfizer owns a portfolio of prescription medicines and vaccines spanning oncology, cardiovascular, immunology, vaccines, and rare diseases. Key products include Eliquis (anticoagulant), Prevnar (pneumococcal vaccine), Ibrance (breast cancer), Vyndaqel (rare heart disease), Paxlovid (COVID-19 antiviral), Comirnaty (COVID-19 vaccine, with BioNTech), and Abrysvo (RSV vaccine). The 2023 acquisition of Seagen added oncology antibody-drug conjugates including Padcev, Adcetris, and Tukysa. The 2025 acquisition of Metsera added obesity treatment candidates to the pipeline.

Is Pfizer publicly traded?
Yes, Pfizer Inc. is listed on the New York Stock Exchange under ticker PFE. The company has been publicly traded since 1944. Pfizer has no single controlling shareholder, with major institutional holders including Vanguard Group, BlackRock, and State Street. Pfizer is a component of the Dow Jones Industrial Average and the S&P 500.

Who founded Pfizer?
Pfizer was founded in 1849 in Brooklyn, New York by Charles Pfizer and his cousin Charles Erhart. Charles Pfizer was a German-born chemist who emigrated to the United States. The company's first product was santonin, an antiparasitic agent. Pfizer's breakthrough into modern pharmaceuticals came during World War II when the company developed large-scale penicillin production using deep-tank fermentation.

Where is Pfizer headquartered?
Pfizer is headquartered in New York City, New York, USA. The company maintains its principal executive offices in Midtown Manhattan. Pfizer operates manufacturing facilities in the United States, Belgium, Ireland, the United Kingdom, Germany, Japan, China, India, and Brazil, and sells products in more than 125 countries worldwide.

How many products does Pfizer sell?
Pfizer sells dozens of prescription medicines and vaccines across multiple therapeutic areas. The company's portfolio includes products in oncology, vaccines, cardiovascular, immunology, rare diseases, and hospital products. Several of Pfizer's products each generate over $1 billion in annual revenue, including Eliquis, Prevnar, Ibrance, and Vyndaqel. The company's research pipeline includes hundreds of compounds in various stages of clinical development.

Who owns Pfizer?
Pfizer Inc. is publicly traded on the NYSE with a broad institutional and retail shareholder base. No single shareholder holds a controlling stake. Major institutional shareholders include Vanguard Group, BlackRock, and State Street. Albert Bourla serves as Chairman and CEO. Pfizer has no founding family or private equity controlling shareholder.

What is Pfizer's financial performance?
For full-year 2025, Pfizer reported revenue of $62.6 billion, a 2% decrease from $63.6 billion in FY2024. Excluding COVID-19 products (Comirnaty and Paxlovid), revenue grew 6% operationally. Net income was $7.77 billion, down 3% from $8.03 billion. Adjusted diluted EPS was $3.22, up 4% from $3.11. Net cash from operations was $11.7 billion. For FY2026, Pfizer projects revenue of $59.5 to $62.5 billion and adjusted diluted EPS of $2.80 to $3.00.

Founded: 1849
Headquarters: New York, New York, USA
Company Type: Publicly Traded
Stock: NYSE: PFE
Revenue: $62.6 billion (FY2025)
Employees: approximately 88,000

Visit Pfizer Inc. website

View full company profile for Pfizer Inc.

Where Is Ibrance Made / Based?

Headquarters: New York, New York, USA
Manufacturing / Operations: United States, Ireland

Ibrance Categories & Tags

Oncology Breast Cancer Cdk46 Inhibitor Prescription Drug Cancer Treatment

Ibrance Sustainability & Ethics

Ibrance is subject to Pfizer's corporate sustainability and access programs rather than product-level certifications. Pfizer operates patient assistance programs covering copay support and free drug supply for eligible uninsured patients in the United States.

Post-market pharmacovigilance is standard for the oncology category. The drug carries labeling for neutropenia, interstitial lung disease, and embryo-fetal toxicity, managed through routine monitoring.

Awards & Recognition

FDA Breakthrough Therapy Designation: Granted before approval, accelerating review
Prix Galien recognition: Ibrance received pharmaceutical innovation honors following its launch as the first CDK4/6 inhibitor
Class creation: Widely cited in oncology literature as the product that established CDK4/6 inhibition as a therapeutic mechanism

Ibrance Recalls & Controversies

Ibrance has not faced product recalls or safety withdrawals. Its controversies are commercial and clinical.

The failure of its adjuvant trials in early breast cancer, where Verzenio succeeded, became a significant competitive setback and a recurring theme in oncology-market coverage. Pfizer's label remains limited to metastatic disease while competitors expanded into curative-intent settings.

Pricing criticism applies as it does across the category. At US list prices in the tens of thousands of dollars per year, Ibrance has been cited in drug-pricing debates over oncology affordability, and its inclusion on Medicare's price negotiation list under the Inflation Reduction Act will reset its US net pricing once generics do not arrive first.

Ibrance Ownership: Pros & Cons

Advantages

+Fully owned by Pfizer with no partner revenue split
+Category-creating product with a decade of real-world prescribing data
+Still among Pfizer's largest oncology revenue lines in FY2025
+Familiar, manageable safety profile supports continued metastatic use

Considerations

-Verzenio's adjuvant approval took the larger early-stage market where Ibrance failed its trials
-Approaching patent expiry opens the path to generic palbociclib competition
-Class share has eroded as survival data favored competitors
-Medicare price negotiation exposure adds further pricing pressure

Frequently Asked Questions About Ibrance

Sources & Further Reading

Competitors to Ibrance

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
TukysaSister Brand	Pfizer	USA	2020	Mass market	Global	All Genders
Opdivo	Bristol Myers Squibb	USA	2014	Mass market	Global	All Genders
Taxotere	Sanofi	France	1996	Established	Global	Unisex
AdcetrisSister Brand	Pfizer	United States	2011	Mass market	North america	All Genders
PadcevSister Brand	Pfizer	USA	2019	Mass market	Global	All Genders
XtandiSister Brand	Pfizer	USA	2012	Mass market	Global	All Genders